Cereton, 250 mg/ml 4 ml 5 pcs

Pharmacodynamics

Cereton is a nootropic. It is a central cholinostimulant containing 40.5% metabolically protected choline. Metabolically protected promotes the release of choline in the brain. It provides synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system and activates reticular formation.

increases linear velocity of blood flow on the side of the traumatic brain injury, promotes normalization of spatiotemporal characteristics: spontaneous bioelectrical activity of the brain, regression of focal neurological symptoms and restoration of consciousness; has a positive effect on the cognitive and behavioral responses of patients with cerebral vascular disease (discirculatory encephalopathy and residual effects of cerebral circulatory disorders).

It has preventive and corrective effect on pathogenetic factors of involutional psychorganic syndrome, changes phospholipid composition of neuron membranes: participates in the synthesis of phosphatidylcholine (membrane phospholipid) and improves neuronal membrane plasticity. Stimulates dose-dependent release of acetylcholine under physiological conditions, improves synaptic transmission and receptor function. It has no effect on the reproductive cycle and has no teratogenic and mutagenic effect.

Pharmacokinetics

When administered parenterally (10 mg/kg) Cereton predominantly accumulates in the brain, lungs and liver. Absorption is 88%, easily penetrates through the blood-brain barrier (when administered orally, the concentration in the brain is 45% of that in plasma). The lungs excrete 85% of the drug as carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestines.

Indications

Active ingredient

Composition

1 ampoule (4 ml of solution for intravenous and intramuscular administration) contains:

the active ingredient:

Glycerylphosphorylcholine hydrate in terms of anhydrous glycerylphosphorylcholine (choline alphosphocerate) – 1000 mg,

auxiliary substances:

water for injection – up to 4 ml.

How to take, the dosage

In acute conditions, administer intravenously (slowly) or deeply intramuscularly at 1000 mg (1 ampoule) per day for 10-15 days.

Special Instructions

Cereton has no effect on the speed of psychomotor reactions.

Contraindications

Side effects

Nausea may occur (mainly as a consequence of dopaminergic activation), in which case the drug dose should be reduced.

Allergic reactions.

Digestive system disorders: constipation, diarrhea, dry oral mucosa, pharyngitis.

Nervous system disorders: headache, drowsiness, insomnia, aggressiveness, anxiety, nervousness, cerebral ischemia, seizures, dizziness.

Skin disorders: rash, urticaria.

Others: pain at the site of injection, increased frequency of urination.

Overdose

Nausea may be noted.

Treatment: symptomatic therapy.

Pregnancy use

The use of the drug Cereton during pregnancy and while breastfeeding is contraindicated.

Breastfeeding should be stopped during treatment with Cereton.

Similarities